Skip to main content

Table 4 Treatment efficacy in acquired angioedema C1-inhibitor patients with anti-C1-INH autoantibodies (N = 8)

From: Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate

Patient Gender
(M/F)
Type of anti-C1-INH autoantibodies Untreated attacks
(n)
Mean duration of untreated attacks
(h)
Treated attacks
(n)
Mean duration of treated attacks a
(h)
Mean shortening of attacks with treatment (h, (%)) Effectively treated attacks b
(n (%))
1 F IgG 124 72 820 9.5 62.5 (86.8) 820 (100)
2 M IgG, IgM 208 60 13 79 −19 (−31.7) 1 (8.3)
3 M IgG 648 84 12 41.5 42.5 (50.6) 12 (100)
4 M IgG, IgM 79 96 16 26 70 (72.9) 16 (100)
5 F IgA 89 84 24 38 46 (54.8) 22 (91.7)
6 M IgG 59 96 303 24.25 71.75 (74.7) 303 (100)
7 M IgG, IgM 144 120 71 11 109 (90.8) 70 (98.6)
8 F IgG, IgM 283 72 70 51.5 20.5 (28.5) 68 (97.1)
Total 1634 1329 1246 (93.8)
  1. atime between onset of attack and injection + time between injection and resolution of symptoms
  2. bas assessed by the patient
  3. C1-INH = C1-inhibitor; F = Female; Ig = Immunoglobulin; M = Male